44 results about "FGF19" patented technology

The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.

Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

The present invention relates to a FGF19 polypeptide for its use as an agent increasing muscle fibers size, in the prevention and/or treatment of muscle atrophy in a mammal body.

Provided herein are methods of treating or preventing gastrointestinal motility-related disorders, treating or preventing constipation or stimulating bowel function, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

Models useful in determining whether fibroblast growth factor 19 variant polypeptides having glucose-lowering activity and/or anti-obesity activity also exhibit favorable oncology-related profiles, and methods and uses associated therewith are provided. Also provided are methods of antagonizing the oncogenic activity of FGF19 in a subject and, in certain embodiments, methods of preventing or treating a disease, disorder or condition, such as a FGF19-dependent disease, disorder or condition, or a symptom thereof.

The invention relates to a detection kit for the copy number of a fibroblast growth factor 19 (FGF19) gene, and belongs to the molecular biology technical field; the kit is composed of a fluorescent quantitative reaction liquid pre-mixed solution, FGF19 target gene sequence PCR amplification primers and internal reference sequence PCR amplification primers. A detection method includes the steps: a sequence on an exon 2 of the FGF19 gene is taken as a template for designing the detection primers, a set of internal reference sequence amplification primers (MRef) is designed in view of a segment of stable sequence randomly uniformly distributed and appearing more than 40 times in a human genome, a target sequence is amplified by using a fluorescent quantitative PCR method, and resulting data is analyzed with the help of a set of on-line analysis software, so as to determine the copy number of the FGF19 gene in different samples. The detection kit has the advantages of high sensitivity, good specificity, and large dynamic range, and the detection method is simple, convenient and quick, and the detection kit can be applied to quantitative detection of the copy number of the FGF19 gene in various tissues, cells and blood samples.

The invention discloses an FGF19 over-expression human liver cancer cell line and application thereof. The GF19 over-expression human liver cancer cell line is preserved in China Center for Type Culture Collection with the preservation number of CCTCC NO:C201663. The above human liver cancer cell has stable properties, can be stably repeatedly passaged, has a high tumorigenesis rate, a short incubation period and a good homogeneity, and provides a new experimental material close to the biological characteristics of clinical tumor for liver cancer researches. The human liver cancer cell line has a tumorigenesis ability after being inoculated into nude mouse bodies; and compared with passage parental tumors, the human liver cancer cell line can be used to analyze the drug sensitivity in vitro and in vivo in order to establish a drug screening platform, and is an ideal cell for the basic research and the preclinical application of the human liver cancer.